Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersUse of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot StudySafety of ultrasound contrast agents in the pediatric oncologic population: a single-institution experience.Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot studyInefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewAdvances in paediatric cancer treatmentPneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.Future directions in the treatment of osteosarcoma.Immunotherapy in pediatric malignancies: current status and future perspectivesCan Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?Alternative formulations of sorafenib for use in children.Emerging drugs for neuroblastoma.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Safety of bevacizumab in patients younger than 4 years of age.Drugs in early clinical development for the treatment of osteosarcoma.Advances in emerging drugs for the treatment of neuroblastoma.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma.Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.Trial Watch: Chemotherapy with immunogenic cell death inducers.Trial watch: Chemotherapy with immunogenic cell death inducers.Sorafenib in patients with progressed and refractory bone tumors
P2860
Q26747666-95F894DC-A23E-473F-839C-30784206001AQ26993238-5ADE85AD-50BC-432E-B941-7174656AA169Q28082793-1B3B107C-58E0-469F-B6C8-B06715F3B00FQ30357444-1F4971CF-1BBD-4630-BF95-E426BFCE29F9Q34781426-775B5208-0C08-43B4-BC51-26D6210F13AAQ34880943-39073DE6-2B46-48C1-9F74-21DF8D370E2FQ35929346-12006CE8-BC16-428D-A540-EDAC9B148466Q36270115-606C81E1-3F91-4220-B360-30353B1575D9Q36508630-CEE546C6-411D-4063-9DC5-68D5B3855F15Q36592628-DEB17972-B667-4027-8488-35E26001265FQ36600800-9B1C31FB-8164-411F-A2EE-055300EE37EAQ36691818-C8CC5A1A-8D3E-445A-9637-76139303292CQ36996436-6A3EE54D-D885-491D-84C0-3C8EF1BC788AQ37239947-DA9CF748-F59C-4316-B35D-C047A6ABAB18Q38108399-CC99E392-09AD-4DAA-A942-9C57CCA4005EQ38130312-030AD9E0-5F14-48B0-AB78-867FB676B506Q38575870-BFF34B5F-49B9-4BE5-9812-45CD93D26556Q38955517-08A6B709-4B1B-46AB-AC91-C674978A4937Q39158415-D4821757-D65C-4EBB-9FFB-A7B5D0AEA34FQ39401628-53A322F2-FFD0-435B-9B62-16E34D3FB300Q42736880-64D04E7B-872A-4B1D-A4FB-CF7D032DFEA5Q47229175-17591770-B9FD-461F-8EFA-7F05E839D336Q52654231-9EA476C7-DCA5-4F18-869E-FCBDEC396CE1Q55260834-BAD11500-4594-4EFD-A468-B6232C33DBC2Q55658029-1DC12333-2A8A-4B8B-9645-DF5B9AE2143DQ58774317-CEE71E89-05D8-45F7-8BCB-F74B09835C45
P2860
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@ast
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@en
type
label
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@ast
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@en
prefLabel
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@ast
Phase I and clinical pharmacol ...... actory/recurrent solid tumors.
@en
P2093
P2860
P1476
Phase I and clinical pharmacol ...... ractory/recurrent solid tumors
@en
P2093
Andrew M Davidoff
Catherine A Billups
Clinton F Stewart
David Turner
Demba Fofana
Fariba Navid
Jianrong Wu
John C Panetta
Lisa M McGregor
M Beth McCarville
P2860
P304
P356
10.1158/1078-0432.CCR-12-1897
P407
P577
2012-11-08T00:00:00Z